Bhuvaneswari Ramaswamy

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity
    Bhuvaneswari Ramaswamy
    Department of Molecular and Cellular Biochemistry, Ohio State University, Columbus, Ohio, USA
    Mol Endocrinol 23:176-87. 2009
  2. ncbi A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors
    Bhuvaneswari Ramaswamy
    The Ohio State University, B401, Starling Loving Hall, 320 W 10th av, Columbus, OH 43210, USA
    Cancer Chemother Pharmacol 66:151-8. 2010
  3. ncbi Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer
    Bhuvaneswari Ramaswamy
    Division of Hematology and Oncology, Ohio State University Medical Center, Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, OH 43210, USA
    Invest New Drugs 29:347-51. 2011
  4. ncbi Pregnancy-associated breast cancer
    Srividya Viswanathan
    Division of Medical Oncology, Arthur G James Cancer Hospital, Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USA
    Clin Obstet Gynecol 54:546-55. 2011
  5. ncbi Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors
    Bhuvaneswari Ramaswamy
    Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio 43210, USA
    Drugs Today (Barc) 42:265-79. 2006
  6. ncbi MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1
    Tyler E Miller
    Department of Molecular and Cellular Biochemistry, College of Medicine, Ohio State University, Columbus, Ohio 43210, USA
    J Biol Chem 283:29897-903. 2008
  7. ncbi Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer
    Ewa Mrozek
    Division of Hematology and Oncology, Comprehensive Cancer Center, Ohio State University Medical Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA
    Clin Breast Cancer 7:141-5. 2006
  8. ncbi Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients
    Bhuvaneswari Ramaswamy
    Division of Hematology/Oncology, The Ohio State University Medical Center, Columbus, Ohio, USA
    Clin Cancer Res 12:3124-9. 2006
  9. ncbi Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal
    Yuanzhi Lu
    Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio 43210, USA
    J Biol Chem 286:42292-302. 2011
  10. ncbi Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer
    Bhuvaneswari Ramaswamy
    Division of Hematology/Oncology and Comprehensive Breast Health Services, Ohio State University Medical Center, Columbus, OH, USA
    Breast Cancer Res Treat 93:67-74. 2005

Collaborators

Detail Information

Publications20

  1. ncbi Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity
    Bhuvaneswari Ramaswamy
    Department of Molecular and Cellular Biochemistry, Ohio State University, Columbus, Ohio, USA
    Mol Endocrinol 23:176-87. 2009
    ..These data suggest that estrogen-mediated suppression of PTPRO is probably one of the early events in estrogen-induced tumorigenesis and that expression of PTPRO could facilitate endocrine therapy of breast cancer...
  2. ncbi A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors
    Bhuvaneswari Ramaswamy
    The Ohio State University, B401, Starling Loving Hall, 320 W 10th av, Columbus, OH 43210, USA
    Cancer Chemother Pharmacol 66:151-8. 2010
    ..A phase I study to determine the maximum tolerated dose (MTD) of bortezomib (B) when combined with weekly paclitaxel in patients with advanced solid tumors...
  3. ncbi Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer
    Bhuvaneswari Ramaswamy
    Division of Hematology and Oncology, Ohio State University Medical Center, Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, OH 43210, USA
    Invest New Drugs 29:347-51. 2011
    ..We conducted a phase II clinical study to determine the efficacy and toxicities of PZA in patients with metastatic breast cancer (MBC). Experimental..
  4. ncbi Pregnancy-associated breast cancer
    Srividya Viswanathan
    Division of Medical Oncology, Arthur G James Cancer Hospital, Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USA
    Clin Obstet Gynecol 54:546-55. 2011
    ....
  5. ncbi Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors
    Bhuvaneswari Ramaswamy
    Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio 43210, USA
    Drugs Today (Barc) 42:265-79. 2006
    ..This article will review the pharmacology and trials leading to the clinical approval of this agent...
  6. ncbi MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1
    Tyler E Miller
    Department of Molecular and Cellular Biochemistry, College of Medicine, Ohio State University, Columbus, Ohio 43210, USA
    J Biol Chem 283:29897-903. 2008
    ..This finding also provides the rationale for the application of altered expression of specific miRNAs as a predictive tamoxifen-resistant breast cancer marker...
  7. ncbi Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer
    Ewa Mrozek
    Division of Hematology and Oncology, Comprehensive Cancer Center, Ohio State University Medical Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA
    Clin Breast Cancer 7:141-5. 2006
    ..5 months (95% CI, 3.7-7.3 months). CONCLUSION: Weekly docetaxel with capecitabine was active with acceptable toxicities. Additional trials to define the optimal schedule of docetaxel and capecitabine are justified...
  8. ncbi Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients
    Bhuvaneswari Ramaswamy
    Division of Hematology/Oncology, The Ohio State University Medical Center, Columbus, Ohio, USA
    Clin Cancer Res 12:3124-9. 2006
    ..CONCLUSION: Bevazicumab in combination with weekly docetaxel is active with acceptable toxicities in MBC. Additional studies evaluating E-selectin as a marker of response to bevacizumab-containing chemotherapy are warranted...
  9. ncbi Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal
    Yuanzhi Lu
    Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio 43210, USA
    J Biol Chem 286:42292-302. 2011
    ..In conclusion, miR-221/222 and -181b facilitate growth factor signaling in tamoxifen-resistant breast cancer by down-regulating TIMP3, and corresponding anti-miRs can be used to render these tumors responsive to tamoxifen...
  10. ncbi Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer
    Bhuvaneswari Ramaswamy
    Division of Hematology/Oncology and Comprehensive Breast Health Services, Ohio State University Medical Center, Columbus, OH, USA
    Breast Cancer Res Treat 93:67-74. 2005
    ..To our knowledge, this is first description of docetaxel-induced activation of mitogen-activated and stress-activated protein kinase pathways in human breast cancer...
  11. ncbi Gene expression profiling: changing face of breast cancer classification and management
    Robert Wesolowski
    Division of Medical Oncology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Gene Expr 15:105-15. 2011
    ..Categorization of breast cancers by gene expression is only beginning to make its way into the daily clinical practice and likely will complement, but not replace, the conventional methods of classification...
  12. ncbi Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer
    Ewa Mrozek
    Division of Medical Oncology, The Ohio State University Medical Center, Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, OH
    Clin Breast Cancer 12:151-6. 2012
    ..We designed a phase II study with the purpose of determining whether combining these 2 drugs with different and potentially complementary mechanisms of action will improve the clinical benefit...
  13. ncbi Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer
    Tao Zuo
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    Cancer Res 71:1752-62. 2011
    ..These combined treatments synergistically relieve gene silencing and suppress cancer cell growth in vitro and in xenografts. The new finding has important implications for improving targeted cancer therapies in the future...
  14. ncbi Bisphosphonates in the prevention and treatment of bone metastases
    Bhuvaneswari Ramaswamy
    Ohio State University Medical Center, Comprehensive Cancer Center, Columbus, Ohio, USA
    Oncology (Williston Park) 17:1261-70; discussion 1270-2, 1277-8, 1280. 2003
    ..Bone loss, a common consequence of cancer treatment, should be treated with the usual measures indicated for the management of osteoporosis, including bisphosphonates...
  15. ncbi A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors
    Bhuvaneswari Ramaswamy
    Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
    Invest New Drugs 30:629-38. 2012
    ....
  16. ncbi Giant breast tumors: surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature
    Margaret I Liang
    Ohio State College of Medicine, Columbus, Ohio, USA
    World J Surg Oncol 6:117. 2008
    ..While the surgical management of these relatively uncommon tumors has been addressed in the literature, few reports have commented on the surgical approach to tumors greater than ten centimeters in diameter - the giant phyllodes tumor...
  17. ncbi Association of major stressors with elevated risk of breast cancer incidence or relapse
    Shubham Pant
    Arthur G James Cancer Hospital and Richard J Solove Research Institute, Ohio State University, Columbus, Ohio 43210, USA
    Drugs Today (Barc) 45:115-26. 2009
    ..The present review outlines the pathophysiological effects of stress and how it may impact on carcinogenesis and enumerates the studies evaluating the association of stressors with the incidence and relapse of breast cancer...
  18. ncbi Docetaxel for the post-surgery treatment of patients with node-positive breast cancer
    Shubham Pant
    Arthur G James Cancer Hospital and Richard J Solove Research Institute, Ohio State University Columbus, Ohio, USA
    Ther Clin Risk Manag 4:419-24. 2008
    ..This article reviews the pharmacology of docetaxel, a semi-synthetic taxane, and the clinical trials supporting its use in patients with node-positive breast cancer...
  19. ncbi Osteopenia and osteoporosis in women with breast cancer
    Bhuvaneswari Ramaswamy
    Department of Medicine, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus 43210, USA
    Semin Oncol 30:763-75. 2003
    ..As many women with breast cancer will be long-term survivors, increasing recognition of maintaining skeletal health is important...
  20. ncbi Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer
    Bhuvaneswari Ramaswamy
    The Ohio State University Medical Center and Comprehensive Cancer Center, Columbus 43210, USA
    Clin Breast Cancer 4:292-4. 2003